메뉴 건너뛰기




Volumn 9, Issue 4, 2014, Pages

Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CISPLATIN; DOXORUBICIN; NUCLEIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

EID: 84898770726     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093996     Document Type: Article
Times cited : (21)

References (35)
  • 1
    • 79958857301 scopus 로고    scopus 로고
    • Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma
    • Crago AM, Singer S (2011) Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 23: 373-378.
    • (2011) Curr Opin Oncol , vol.23 , pp. 373-378
    • Crago, A.M.1    Singer, S.2
  • 2
    • 77149149403 scopus 로고    scopus 로고
    • Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience
    • de Vreeze RS, de Jong D, Nederlof PM, Ariaens A, Tielen IH, et al. (2010) Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience. Ann Surg Oncol 17: 686-693.
    • (2010) Ann Surg Oncol , vol.17 , pp. 686-693
    • De Vreeze, R.S.1    De Jong, D.2    Nederlof, P.M.3    Ariaens, A.4    Tielen, I.H.5
  • 3
    • 12744274528 scopus 로고    scopus 로고
    • Diagnosis, classification, and management of soft tissue sarcomas
    • Mankin HJ, Hornicek FJ (2005) Diagnosis, classification, and management of soft tissue sarcomas. Cancer Control 12: 5-21.
    • (2005) Cancer Control , vol.12 , pp. 5-21
    • Mankin, H.J.1    Hornicek, F.J.2
  • 4
    • 84883879096 scopus 로고    scopus 로고
    • Moderate to vigorous physical activity and weight outcomes: Does every minute count?
    • Fan JX, Brown BB, Hanson H, Kowaleski-Jones L, Smith KR, et al. (2013) Moderate to vigorous physical activity and weight outcomes: does every minute count? Am J Health Promot 28: 41-49.
    • (2013) Am J Health Promot , vol.28 , pp. 41-49
    • Fan, J.X.1    Brown, B.B.2    Hanson, H.3    Kowaleski-Jones, L.4    Smith, K.R.5
  • 5
    • 84878373098 scopus 로고    scopus 로고
    • Phylogenetic analysis of symbionts in feather-feeding lice of the genus Columbicola: Evidence for repeated symbiont replacements
    • Smith WA, Oakeson KF, Johnson KP, Reed DL, Carter T, et al. (2013) Phylogenetic analysis of symbionts in feather-feeding lice of the genus Columbicola: evidence for repeated symbiont replacements. BMC Evol Biol 13: 109.
    • (2013) BMC Evol Biol , vol.13 , pp. 109
    • Smith, W.A.1    Oakeson, K.F.2    Johnson, K.P.3    Reed, D.L.4    Carter, T.5
  • 6
  • 8
    • 73949143761 scopus 로고    scopus 로고
    • Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: A review
    • Tanas MR, Goldblum JR (2009) Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol 16: 383-391.
    • (2009) Adv Anat Pathol , vol.16 , pp. 383-391
    • Tanas, M.R.1    Goldblum, J.R.2
  • 10
    • 79952216562 scopus 로고    scopus 로고
    • Liposarcoma: Molecular genetics and therapeutics
    • Conyers R, Young S, Thomas DM (2011) Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011: 483154.
    • (2011) Sarcoma , vol.2011 , pp. 483154
    • Conyers, R.1    Young, S.2    Thomas, D.M.3
  • 15
    • 0031713434 scopus 로고    scopus 로고
    • No correlation of c-myc overexpression and p53 mutations in liposarcomas
    • DOI 10.1007/s004280050255
    • Schneider-Stock R, Walter H, Rys J, Radig K, Hoang-Vu C, et al. (1998) No correlation of c-myc overexpression and p53 mutations in liposarcomas. Virchows Arch 433: 315-321. (Pubitemid 28477032)
    • (1998) Virchows Archiv , vol.433 , Issue.4 , pp. 315-321
    • Schneider-Stock, R.1    Walter, H.2    Rys, J.3    Radig, K.4    Hoang-Vu, C.5    Roessner, A.6
  • 18
    • 84875155842 scopus 로고    scopus 로고
    • Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition
    • Smith KB, Tran LM, Tam BM, Shurell EM, Li Y, et al. (2013) Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition. Am J Pathol 182: 1400-1411.
    • (2013) Am J Pathol , vol.182 , pp. 1400-1411
    • Smith, K.B.1    Tran, L.M.2    Tam, B.M.3    Shurell, E.M.4    Li, Y.5
  • 19
    • 77954566882 scopus 로고    scopus 로고
    • Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine
    • Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, et al. (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2: 146-158.
    • (2010) EMBO Mol Med , vol.2 , pp. 146-158
    • Dias-Santagata, D.1    Akhavanfard, S.2    David, S.S.3    Vernovsky, K.4    Kuhlmann, G.5
  • 21
    • 77952518695 scopus 로고    scopus 로고
    • Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma
    • Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, et al. (2010) Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett 293: 220-229.
    • (2010) Cancer Lett , vol.293 , pp. 220-229
    • Duan, Z.1    Ji, D.2    Weinstein, E.J.3    Liu, X.4    Susa, M.5
  • 22
    • 35548976764 scopus 로고    scopus 로고
    • 8-Benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel Janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells
    • DOI 10.1124/mol.107.038117
    • Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, et al. (2007) 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol 72: 1137-1145. (Pubitemid 350012588)
    • (2007) Molecular Pharmacology , vol.72 , Issue.5 , pp. 1137-1145
    • Duan, Z.1    Bradner, J.2    Greenberg, E.3    Mazitschek, R.4    Foster, R.5    Mahoney, J.6    Seiden, M.V.7
  • 23
    • 84865794821 scopus 로고    scopus 로고
    • Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation
    • Duan Z, Zhang J, Choy E, Harmon D, Liu X, et al. (2012) Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin Cancer Res 18: 4580-4588.
    • (2012) Clin Cancer Res , vol.18 , pp. 4580-4588
    • Duan, Z.1    Zhang, J.2    Choy, E.3    Harmon, D.4    Liu, X.5
  • 24
  • 25
    • 84860863911 scopus 로고    scopus 로고
    • PI3K and mTOR signaling pathways in cancer: New data on targeted therapies
    • Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, et al. (2012) PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 14: 129-138.
    • (2012) Curr Oncol Rep , vol.14 , pp. 129-138
    • Willems, L.1    Tamburini, J.2    Chapuis, N.3    Lacombe, C.4    Mayeux, P.5
  • 27
    • 70349974841 scopus 로고    scopus 로고
    • The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
    • Westhoff MA, Kandenwein JA, Karl S, Vellanki SH, Braun V, et al. (2009) The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 28: 3586-3596.
    • (2009) Oncogene , vol.28 , pp. 3586-3596
    • Westhoff, M.A.1    Kandenwein, J.A.2    Karl, S.3    Vellanki, S.H.4    Braun, V.5
  • 28
    • 79952183554 scopus 로고    scopus 로고
    • PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
    • Agell L, Hernandez S, Salido M, de Muga S, Juanpere N, et al. (2011) PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod Pathol 24: 443-452.
    • (2011) Mod Pathol , vol.24 , pp. 443-452
    • Agell, L.1    Hernandez, S.2    Salido, M.3    De Muga, S.4    Juanpere, N.5
  • 29
    • 80555157475 scopus 로고    scopus 로고
    • Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
    • Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, et al. (2011) Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 121: 4311-4321.
    • (2011) J Clin Invest , vol.121 , pp. 4311-4321
    • Ebi, H.1    Corcoran, R.B.2    Singh, A.3    Chen, Z.4    Song, Y.5
  • 30
    • 77955090106 scopus 로고    scopus 로고
    • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
    • Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, et al. (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42: 715-721.
    • (2010) Nat Genet , vol.42 , pp. 715-721
    • Barretina, J.1    Taylor, B.S.2    Banerji, S.3    Ramos, A.H.4    Lagos-Quintana, M.5
  • 31
    • 78651385352 scopus 로고    scopus 로고
    • A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models
    • Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K (2011) A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 71: 154-163.
    • (2011) Cancer Res , vol.71 , pp. 154-163
    • Bagci-Onder, T.1    Wakimoto, H.2    Anderegg, M.3    Cameron, C.4    Shah, K.5
  • 32
    • 79956017530 scopus 로고    scopus 로고
    • Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma
    • Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, et al. (2011) Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin Cancer Res 17: 3233-3247.
    • (2011) Clin Cancer Res , vol.17 , pp. 3233-3247
    • Opel, D.1    Naumann, I.2    Schneider, M.3    Bertele, D.4    Debatin, K.M.5
  • 33
    • 67650928195 scopus 로고    scopus 로고
    • Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma
    • Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, et al. (2009) Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res 29: 1867-1871.
    • (2009) Anticancer Res , vol.29 , pp. 1867-1871
    • Schwab, J.1    Antonescu, C.2    Boland, P.3    Healey, J.4    Rosenberg, A.5
  • 35
    • 79951958286 scopus 로고    scopus 로고
    • New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort
    • Hoffman A, Lazar AJ, Pollock RE, Lev D (2011) New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat 14: 52-66.
    • (2011) Drug Resist Updat , vol.14 , pp. 52-66
    • Hoffman, A.1    Lazar, A.J.2    Pollock, R.E.3    Lev, D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.